Takeda Pharmaceutical's strong earnings, dividends, and strategic moves make it an appealing investment despite US policy ...

The emphasis on the half-dozen future medicines will be essential for Takeda as the company’s lead product, Entyvio, inches toward expected biosimilar competition in 2031. As it stands ...

The FDA has approved the first and only subcutaneous apomorphine infusion device, apomorphine hydrochloride injection (Onapgo ...

The Dec. 27, 2024, Food and Drug Administration (FDA) approval of the subcutaneous injection formulation of Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) for patients with solid tumors opened up ...

Most recently, the Food and Drug Administration (FDA) approved treatment with the subcutaneous injection formulation of Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) for patients with solid tumors ...

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.

“When you inject yourself with, for example, insulin, you inject into subcutaneous fat, but these patients don’t have that,” ...

The FDA has accepted Eisai and Biogen’s biologics license application for a monthly infusion of IV Leqembi to treat ...

With this approval, HYQVIA [Immune Globulin Infusion 10% (human) with Recombinant Human Hyaluronidase] becomes the first and only facilitated subcutaneous immunoglobulin available in Japan to treat ...

Subcutaneous immunotherapy (SCIT) is a unique therapy for allergic disease because it provides symptomatic relief while modifying the allergic disease by targeting the underlying immunological ...

A major new study has highlighted significant health risks associated with popular weight loss injections such as Ozempic, Wegovy, and Mounjaro. The research involved over two million patients and ...

Instead, he listed them on iPads handed to patients after they arrived, and instructed his employees never to take pictures of him performing injections, prosecutors said. When clients complained ...